ImmunID Receives CLIA Certification from the US Centers for Medicare & Medicaid Services

Company Achieves Significant Regulatory and Commercial Milestone GRENOBLE, France, May 3, 2016 /PRNewswire/ — ImmunID, the immune companion diagnostics for precision medicine company, today announced certification from the US Department of Health and Human Services' Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA) for its laboratory in Grenoble, France. Under […]

ImmunTraCkeR® Results on Prediction of Response to Cancer Immunotherapy Selected for Presentation at ASCO Annual Meeting

GRENOBLE, France, March 31, 2016 /PRNewswire/ — ImmunID, the immune companion diagnostics for precision medicine company, today announces that a collaborative work on prediction of response to the anti-PD1 and anti-CTLA-4 immune checkpoint inhibitors in melanoma using ImmunTraCkeR® has been selected for a poster presentation during the American Society for Clinical Oncology (ASCO) Annual Meeting in […]

ImmunID Announces Incorporation and US Development Plans

GRENOBLE, France, March 16, 2016 /PRNewswire/ — ImmunID, the immune companion diagnostics for precision medicine company, today announces the incorporation of a US subsidiary, ImmunID Inc. The new company will support the development of ImmunID's activities in the United States and the access of ImmunTraCkeR® to American patients. Dr. Bernhard Sixt, Chairman and Chief Executive Officer […]

ImmunID Signs Master Collaboration Agreement With MSK About the Prediction of Response to Immuno-Oncology Agents Using ImmunTraCkeR®

GRENOBLE, France, Feb. 23, 2016 /PRNewswire/ — ImmunID, the immune companion diagnostics for precision medicine company, today announces that it has just signed a master collaboration agreement with Memorial Sloan Kettering Cancer Center (MSK) in New York, United States. MSK is the world's oldest and largest private cancer center. It has ranked as one of the […]

Collaboration led by ImmunID Awarded Innovate UK Grant to Advance Program on Prediction of Response to Cancer Immunotherapy using ImmunTraCkeR®

GRENOBLE, France and LONDON and LEEDS, United Kingdom, Feb. 15, 2016 /PRNewswire/ — ImmunID, the immune companion diagnostics for precision medicine company, today announced it has been awarded Small Business Research Initiative funding1 by Innovate UK, UK's innovation agency, to advance its ImmunTraCkeR® assay for therapeutic response prediction. The project aims at validating ImmunID's clinical results with […]

IRX Therapeutics and ImmunID Announce Collaboration to Predict Response to IRX-2 Cancer Immunotherapy Using ImmunTraCkeR®

NEW YORK and GRENOBLE, France, Jan. 19, 2016 /PRNewswire/ — IRX Therapeutics, a clinical-stage bioresearch company developing cancer immunotherapies, and ImmunID, an immune molecular diagnostics and precision medicine company, today announced they have entered into a collaboration agreement for prediction of response to the IRX-2 immunotherapy candidate using the ImmunTraCkeR® assay. Under the collaboration, ImmunID […]

ImmunID Strengthens its Intellectual Property Position with the Issuance of a Key Technology Patent in China

GRENOBLE, France, Dec. 14, 2015 /PRNewswire/ — ImmunID, the immune companion diagnostics company, today announced the granting of a key patent in China. This patent (WO 2009095567) covers the multi-N-plex® Polymerase Chain Reaction (PCR) technology underlying the ImmunTraCkeR® and ImmunIG® assays. ImmunTraCkeR® and ImmunIG® evaluate a patient's own immune status, based on T cell repertoire diversity […]

ImmunID Key Technology Patents Covering ImmunTraCkeR® and ImmunIG® Granted in the United States, Europe, Canada and Japan

GRENOBLE, France, July 22, 2015 /PRNewswire/ — ImmunID today announced the granting of key patents in the United States, Europe, Canada and Japan. These patents cover the underlying technology of the ImmunTraCkeR® and ImmunIG® assays, which are evaluating a patient's own immune system, both T-Cell repertoire and B-Cell repertoire. ImmunTraCkeR® has demonstrated clinical utility predicting response […]

Data Advancing the Clinical Utility of ImmunID's ImmunTraCkeR® for Prediction of Response to Immune Checkpoint Inhibitors Published in the Journal for ImmunoTherapy of Cancer

GRENOBLE, France, July 7, 2015 /PRNewswire/ — ImmunID today announced the publication of a short report in the Journal for ImmunoTherapy of Cancer (JITC) showing that the analysis of peripheral T cell receptor diversity using the company's ImmunTraCkeR® assay is associated with clinical outcomes following Ipilimumab treatment in metastatic melanoma. Results from the study, conducted at […]

ImmunID Receives Accreditation From College of American Pathologists

GRENOBLE, France, June 30, 2015 /PRNewswire/ — The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to ImmunID's laboratory (Grenoble, France) based on results of a recent on-site inspection as part of the CAP's Accreditation Programs. The facility's director, Jean-Francois Mouret, PharmD, was advised of this national recognition and congratulated for the […]

ImmunID Announces Rapid Enrolment of Patients in its PREDICT-ID Melanoma Clinical Trial for Prediction of Response to an Immunotherapy

GRENOBLE, France, Jan. 22, 2015 /PRNewswire/ — ImmunID, an immune molecular diagnostics company, announced today the enrolment of the first five patients in its PREDICT-ID Melanoma study to assess the predictive value of immune profiles for response to Ipilimumab®, an immunomodulatory agent. One month after receiving authorization from the French regulatory bodies for the PREDICT-ID […]

ImmunID Receives Authorization to Start Its PREDICT-ID Clinical Trial in Metastatic Melanoma Patients Treated With an Immune Checkpoint Inhibitor

Multicenter clinical study authorized in France, with principal investigators Pr Luc Thomas and Pr Stephane Dalle, Hospices Civils de Lyon; patient enrollment expected to start in January 2015. GRENOBLE, France, Dec. 10, 2014 /PRNewswire/ — ImmunID, an immune molecular diagnostics company, announced today that the ethic committee and regulatory bodies have granted authorizations to start its […]

Data Advancing the Clinical Utility of ImmunID's ImmunTraCkeR® Test for Prediction of Response to Ipilimumab Immunotherapy to Be Presented at the SITC Annual Meeting

GRENOBLE, France, Nov. 4, 2014 /PRNewswire/ — ImmunID announced today that an abstract has been accepted for oral presentation at the Society for Immunotherapy of Cancer Annual Meeting being held November 6 to 9, 2014 in National Harbor, MD. The abstract titled "T cell receptor diversity evaluation to predict patient response to Ipilimumab in metastatic melanoma" […]

ImmunID Continues to Strengthen its Scientific and Medical Advisory Board with Dr Miguel-Angel Perales

GRENOBLE, France, July 8, 2014 /PRNewswire/ — ImmunID announced today that Dr Miguel Perales, Deputy Chief, Adult Bone Marrow Transplant Service and Director, Adult Stem Cell Transplant Fellowship at Memorial Sloan Kettering Cancer Center in New York, is joining its Scientific Advisory Board. Dr Perales' clinical practice focuses on allogeneic and autologous stem cell transplantation for […]

ImmunID Announces Agreement with the Singapore Immunology Network (SIgN) to Study Immune Competence

GRENOBLE, France, July 1, 2014 /PRNewswire/ — ImmunID, a French Immune Molecular Diagnostics company, today embarked on an agreement with the Singapore Immunology Network (SIgN), a research institute under the Agency of Science, Technology and Research (A*STAR), Singapore. Under the agreement, ImmunID will use its proprietary ImmunTraCkeR® and ImmunIG® tests to evaluate T and B immune […]